Top

Published in:

Open Access 01-12-2023 | Hepatocellular Carcinoma | Research

The potential immuno-stimulating effect of curcumin, piperine, and taurine combination in hepatocellular carcinoma; a pilot study

Authors: Raghda R. kotb, Ahmed M. Afifi, Motawa E. EL-Houseini, Mohamed Ezz-Elarab, Emad B. Basalious, Mervat M. Omran, Mona S. Abdellateif

Published in: Discover Oncology | Issue 1/2023

Abstract

Background

This is a phase II clinical trial to investigate the immunotherapeutic effect of Curcumin, Piperine, and Taurine (CPT) combination in hepatocellular carcinoma (HCC).

Methods

Twenty-six HCC patients aged (50–80 years) were recruited for administration of a daily dose of 5 g of curcumin, 50 mg of piperine, and 500 mg of taurine divided into three doses for successive 3 months. The three components (CPT) were prepared in one capsule. Patients were assessed after each month (cycle) for the plasma levels of CD4, CD8, CD25, Interleukins-2 (IL-2), IL-6, IL-12, Interferon-gamma (IFN- γ), Lactate dehydrogenase (LDH), and Vascular endothelial growth factor (VEGF), FOXP3 mRNA, and miRNA 21.

Results

There was a significant increase in the plasma levels of CD4 and CD8, while a significant decrease in the CD25 level after the second and third cycles compared to the baseline level [P < 0.001 for both]. Also, there was a significant increase in the plasma levels of IL-2, IL-12, and IFN-γ [ P = 0.001, P = 0.006, and P = 0.029; respectively], while there was a significant decrease in IL-6, VEGF-α, LDH, and Alpha-fetoprotein (AFP) after CPT administration compared to the baseline levels [P < 0.001, P < 0.001, P = 0.020, and P = 0.004; respectively].

The expression level of miRNA-21 was significantly decreased after CPT administration compared to the baseline level [5.5±0.88, 4.1±0.78, 3±0.75, and 2.5±0.76; respectively, P<0.001]. Though there was a noticeable decrease in the FOXP3 expression after each cycle, however, it didn’t reach a significant level [5.3±0.8, 4.2±0.76, 3.2±0.67, and 2.5±0.79; respectively, P=0.184].

Conclusion

CPT could exhibit a potential immune-stimulating effect in HCC patients. The current trial had been registered at the National Hepatology and Tropical Medicine Research Institute (NHTMRI), with a registration number of NHTMRI-IRB 2-21 on 5th January 2021.

Available only for authorised users

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. https://doi.org/10.1038/s41572-020-00240-3.CrossRefPubMed

Getachew S, Getachew E, Gizaw M, Ayele W, Addissie A, Kantelhardt EJ. Cervical cancer screening knowledge and barriers among women in Addis Ababa, Ethiopia. PLoS ONE. 2019;14(5):e0216522. https://doi.org/10.1371/journal.pone.0216522.CrossRefPubMedPubMedCentral

Bahnassy AA, Abdellateif MS, Zekri AN. Cancer in Africa: is it a genetic or environmental. Health problem? Front Oncol. 2020;10:604214. https://doi.org/10.3389/fonc.2020.604214.CrossRefPubMedPubMedCentral

Lee TK, Guan XY, Ma S. Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications. Nat Rev Gastroenterol Hepatol. 2022;19(1):26–44. https://doi.org/10.1038/s41575-021-00508-3.CrossRefPubMed

Lu W, Jin XL, Yang C, et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: a single-center randomized controlled trial. Cancer Biol Ther. 2017;18(6):433–8. https://doi.org/10.1080/15384047.2017.1323589.CrossRefPubMedPubMedCentral

Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5(1):146. https://doi.org/10.1038/s41392-020-00264-x.CrossRefPubMedPubMedCentral

Chen Z, Xie H, Hu M, et al. Recent progress in treatment of hepatocellular carcinoma. Am J Cancer Res. 2020;10(9):2993–3036.PubMedPubMedCentral

Jadlowiec CC, Taner T. Liver transplantation: current status and challenges. World J Gastroenterol. 2016;22:4438–45. https://doi.org/10.3748/wjg.v22.i18.4438.CrossRefPubMedPubMedCentral

10.

El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–27. https://doi.org/10.1056/NEJMra1001683.CrossRefPubMed

11.

Liang HH, Wei PL, Hung CS, Wu CT, Wang W, Huang MT, et al. MicroRNA-200a/b influenced the therapeutic effects of curcumin in hepatocellular carcinoma (HCC) cells. Tumour Biol. 2013;34(5):3209–18. https://doi.org/10.1007/s13277-013-0891-z.CrossRefPubMed

12.

Abrahams S, Haylett WL, Johnson G, Carr JA, Bardien S. Antioxidant effects of curcumin in models of neurodegeneration, aging, oxidative and nitrosative stress: a review. Neuroscience. 2019;406:1–21. https://doi.org/10.1016/j.neuroscience.2019.02.020.CrossRefPubMed

13.

Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol. 2007;595:105–25. https://doi.org/10.1007/978-0-387-46401-5_3.CrossRefPubMed

14.

Mollazadeh H, Cicero AFG, Blesso CN, Pirro M, Majeed M, Sahebkar A. Immune modulation by curcumin: the role of interleukin-10. Crit Rev Food Sci Nutr. 2019;59(1):89–101. https://doi.org/10.1080/10408398.2017.1358139.CrossRefPubMed

15.

Zhu J, Zhao B, Xiong P, Wang C, Zhang J, Tian X, et al. Curcumin induces autophagy via inhibition of yes-associated protein (yap) in human colon cancer cells. Med Sci Monit. 2018;24:7035–42. https://doi.org/10.12659/MSM.910650.CrossRefPubMedPubMedCentral

16.

Sun C, Zhang S, Liu C, Liu X. Curcumin promoted mir-34a expression and suppressed proliferation of gastric cancer cells. Cancer Biother Radiopharm. 2019;34(10):634–41. https://doi.org/10.1089/cbr.2019.2874.CrossRefPubMed

17.

Wan Mohd Tajuddin WNB, Lajis NH, Abas F, Othman I, Naidu R. Mechanistic understanding of curcumin’s therapeutic effects in lung cancer. Nutrients. 2019;11(12):2989. https://doi.org/10.3390/nu11122989.CrossRefPubMedPubMedCentral

18.

Calaf GM, Ponce-Cusi R, Carrión F. Curcumin and paclitaxel induce cell death in breast cancer cell lines. Oncol Rep. 2018;40(4):2381–8. https://doi.org/10.3892/or.2018.6603.CrossRefPubMed

19.

Ren B, Luo S, Tian X, Jiang Z, Zou G, Xu F, et al. Curcumin inhibits liver cancer by inhibiting damp molecule hsp70 and tlr4 signaling. Oncol Rep. 2018;40(2):895–901. https://doi.org/10.3892/or.2018.6485Abstract.CrossRefPubMed

20.

Zheng R, Deng Q, Liu Y, Zhao P. Curcumin inhibits gastric Carcinoma Cell Growth and induces apoptosis by suppressing the Wnt/β-Catenin signaling pathway. Med Sci Monit. 2017;23:163–71. https://doi.org/10.12659/msm.902711.CrossRefPubMedPubMedCentral

21.

Xu X, Qin J, Liu W. Curcumin inhibits the invasion of thyroid cancer cells via down-regulation of PI3K/Akt signaling pathway. Gene. 2014;546(2):226–32. https://doi.org/10.1016/j.gene.2014.06.006.CrossRefPubMed

22.

Zhang L, Cheng X, Gao Y, Zhang C, Bao J, Guan H, et al. Curcumin inhibits metastasis in human papillary thyroid carcinoma BCPAP cells via down-regulation of the TGF-β/Smad2/3 signaling pathway. Exp Cell Res. 2016;341(2):157–65. https://doi.org/10.1016/j.yexcr.2016.01.006.CrossRefPubMed

23.

Liang WF, Gong YX, Li HF, Sun FL, Li WL, Chen DQ, et al. Curcumin activates ROS signaling to promote pyroptosis in hepatocellular carcinoma HepG2 cells. In Vivo. 2021;35(1):249–57. https://doi.org/10.21873/invivo.12253.CrossRefPubMedPubMedCentral

24.

Bai C, Zhao J, Su J, Chen J, Cui X, Sun M, et al. Curcumin induces mitochondrial apoptosis in human hepatoma cells through BCLAF1-mediated modulation of PI3K/AKT/GSK-3β signaling. Life Sci. 2022;306:120804. https://doi.org/10.1016/j.lfs.2022.120804.CrossRefPubMed

25.

Guo L, Li H, Fan T, Ma Y, Wang L. Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma. Life Sci. 2021;279:119359. https://doi.org/10.1016/j.lfs.2021.119359.CrossRefPubMed

26.

Li J, Wei H, Liu Y, Li Q, Guo H, Guo Y, et al. Curcumin inhibits Hepatocellular carcinoma via regulating miR-21/TIMP3 Axis. Evid Based Complement Alternat Med. 2020;2020:2892917. https://doi.org/10.1155/2020/2892917.CrossRefPubMedPubMedCentral

27.

Aerts L, Van Assche FA. Taurine and taurine-deficiency in the perinatal period. J Perinat Med. 2002;30(4):281–6. https://doi.org/10.1515/JPM.2002.040.CrossRefPubMed

28.

Räihä NC, Heinonen K, Rassin DK, Gaull GE. Milk protein quantity and quality in low-birthweight infants: I. metabolic responses and effects on growth. Pediatrics. 1976;57(5):659–84.CrossRefPubMed

29.

Chesney RW. Taurine: its biological role and clinical implications. Adv Pediatr. 1985;32:1–42.PubMed

30.

Schaffer SW, Jong CJ, Ito T, Azuma J. Effect of taurine on ischemiareperfusion injury. Amino Acids. 2014;46:21–30. 10.1007/ s00726-012-1378-8.CrossRefPubMed

31.

Marcinkiewicz J, Kontny E. Taurine and inflammatory diseases. Amino Acids. 2014;46:7–20. https://doi.org/10.1007/s00726-012-1361-4.CrossRefPubMed

32.

Wang J, Qi C, Liu L, Zhao L, Cui W, Tian Y, et al. Taurine protects primary neonatal cardiomyocytes against apoptosis induced by hydrogen peroxide. Int Heart J. 2018;59:190–6. https://doi.org/10.1536/ihj.16-372.CrossRefPubMed

33.

Li H, Ruan WJ, Liu LQ, Wan HF, Yang XH, Zhu WF, et al. Impact of taurine on the proliferation and apoptosis of human cervical carcinoma cells and its mechanism. Chin Med J (Engl). 2019;132(8):948–56. https://doi.org/10.1097/CM9.0000000000000162.CrossRefPubMed

34.

Tu S, Zhang XL, Wan HF, Xia YQ, Liu ZQ, Yang XH, et al. Effect of taurine on cell proliferation and apoptosis human lung cancer A549 cells. Oncol Lett. 2018;15:5473–80. https://doi.org/10.3892/ol.2018.8036.CrossRefPubMedPubMedCentral

35.

Zhang X, Lu H, Wang Y, Liu C, Zhu W, Zheng S, et al. Taurine induces apoptosis of breast cancer cells by regulating apoptosisrelated proteins of mitochondria. Int J Mol Med. 2015;35:218–26. https://doi.org/10.3892/ijmm.2014.2002.CrossRefPubMed

36.

Tu S, Zhang X, Luo D, Liu Z, Yang X, Wan H, et al. Effect of taurine on proliferation and apoptosis of human hepatocellular carcinoma (HHCC) HepG2 cells. Exp Ther Med. 2015;10:193–200. https://doi.org/10.3892/etm.2015.2476.CrossRefPubMedPubMedCentral

37.

Haq IU, Imran M, Nadeem M, Tufail T, Gondal TA, Mubarak MS, Piperine. A review of its biological effects. Phytother Res. 2021;35(2):680–700. https://doi.org/10.1002/ptr.6855.CrossRefPubMed

38.

Smilkov K, Ackova DG, Cvetkovski A, Ruskovska T, Vidovic B, Atalay M. Piperine: old spice and New Nutraceutical? Curr Pharm Des. 2019;25(15):1729–39. https://doi.org/10.2174/1381612825666190701150803.CrossRefPubMed

39.

Samuel M, Oliver SV, Coetzee M, Brooke BD. The larvicidal effects of black pepper (Piper nigrum L.) and piperine against insecticide resistant and susceptible strains of anopheles malaria vector mosquitoes. Parasit Vectors. 2016;9:238. https://doi.org/10.1186/s13071-016-1521-6.CrossRefPubMedPubMedCentral

40.

Philipova I, Valcheva V, Mihaylova R, Mateeva M, Doytchinova I, Stavrakov G. Synthetic piperine amide analogs with antimycobacterial activity. Chem Biol Drug Des. 2018;91(3):763–8. https://doi.org/10.1111/cbdd.13140.CrossRefPubMed

41.

Meghwal M, Goswami TK. Piper nigrum and piperine: an update. Phytother Res. 2013;27(8):1121–30. https://doi.org/10.1002/ptr.4972.CrossRefPubMed

42.

de Souza Grinevicius VM, Kviecinski MR, Santos Mota NS, Ourique F, Porfirio Will Castro LS, Andreguetti RR, et al. Piper nigrum ethanolic extract rich in piperamides causes ROS overproduction, oxidative damage in DNA leading to cell cycle arrest and apoptosis in cancer cells. J Ethnopharmacol. 2016;189:139–47. https://doi.org/10.1016/j.jep.2016.05.020.CrossRefPubMed

43.

Ding Y, Ding Y, Wang Y, Wang C, Gao M, Xu Y, et al. Soluplus®/TPGS mixed micelles for co-delivery of docetaxel and piperine for combination cancer therapy. Pharm Dev Technol. 2020;25(1):107–15. https://doi.org/10.1080/10837450.2019.1679834.CrossRefPubMed

44.

Yoo ES, Choo GS, Kim SH, Woo JS, Kim HJ, Park YS, et al. Antitumor and apoptosis-inducing Effects of Piperine on Human Melanoma cells. Anticancer Res. 2019;39(4):1883–92. https://doi.org/10.21873/anticanres.13296.CrossRefPubMed

45.

Sehgal A, Kumar M, Jain M, Dhawan DK. Combined effects of curcumin and piperine in ameliorating benzo(a)pyrene induced DNA damage. Food Chem Toxicol. 2011;49(11):3002–6. https://doi.org/10.1016/j.fct.2011.07.058.CrossRefPubMed

46.

Kakarala M, Brenner DE, Korkaya H, Cheng C, Tazi K, Ginestier C, et al. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat. 2010;122(3):777–85. https://doi.org/10.1007/s10549-009-0612-x.CrossRefPubMed

47.

Hosseini A, Ghorbani A. Cancer therapy with phytochemicals: evidence from clinical studies. Avicenna J Phytomed. 2015;5(2):84–97.PubMedPubMedCentral

48.

Afifi AM, El-Husseiny AM, Tabashy RH, Khalil MA, El-Houseini ME. Sorafenib- taurine combination model for hepatocellular carcinoma cells: immunological aspects. Asian Pac J Cancer Prev. 2019;20(10):3007–13. https://doi.org/10.31557/APJCP.2019.20.10.3007.CrossRefPubMedPubMedCentral

49.

El-Houseini ME, El-Agoza IA, Sakr MM, El-Malky GM. Novel protective role of curcumin and taurine combination against experimental hepatocarcinogenesis. Exp Ther Med. 2017;13(1):29–36. https://doi.org/10.3892/etm.2016.3952.CrossRefPubMed

50.

Hatab HM, Abdel Hamid FF, Soliman AF, Al-Shafie TA, Ismail YM, El-Houseini ME. A combined treatment of curcumin, piperine, and taurine alters the circulating levels of IL-10 and miR-21 in hepatocellular carcinoma patients: a pilot study. J Gastrointest Oncol. 2019;10(4):766–76. https://doi.org/10.21037/jgo.2019.03.07.CrossRefPubMedPubMedCentral

51.

Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. Foods. 2017;6(10):92. https://doi.org/10.3390/foods6100092.CrossRefPubMedPubMedCentral

52.

McGurk KA, Kasapi M, Ware JS. Effect of taurine administration on symptoms, severity, or clinical outcome of dilated cardiomyopathy and heart failure in humans: a systematic review. Wellcome Open Res. 2022;7:9. https://doi.org/10.12688/wellcomeopenres.17505.3.CrossRefPubMedPubMedCentral

53.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–8. https://doi.org/10.1006/meth.2001.1262.CrossRefPubMed

54.

Tang DQ, Bian TT, Zheng XX, Li Y, Wu XW, Li YJ, et al. LC-MS/MS methods for the determination of edaravone and/or taurine in rat plasma and its application to a pharmacokinetic study. Biomed Chromatogr. 2014;28(9):1173–82. https://doi.org/10.1002/bmc.3139.CrossRefPubMed

55.

Wang XM, Zhang QZ, Yang J, Zhu R, Zhang J, Cai LJ, et al. Validated HPLC–MS/MS method for simultaneous determination of curcumin and piperine in human plasma. Trop J Pharm Res. 2012;11(4):621–9.CrossRef

56.

Fu G, Miao L, Wang M, Guo M, Wang C, Ji F, et al. The postoperative immunosuppressive phenotypes of peripheral T helper cells are associated with poor prognosis of breast cancer patients. Immunol Invest. 2017;46:647–62.CrossRefPubMed

57.

Liu C, Wu S, Meng X, Liu G, Chen D, Cong Y, et al. Predictive value of peripheral regulatory T cells in non-small cell lung cancer patients undergoing radiotherapy. Oncotarget. 2017;8:43427–38.CrossRefPubMedPubMedCentral

58.

Li F, Sun Y, Huang J, Xu W, Liu J, Yuan Z. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis. Cancer Med. 2019;8:7330–44.CrossRefPubMedPubMedCentral

59.

Bhattacharyya S, Md Hossain SD, Mohanty S, Sen SG, Chattopadhyay S, Banerjee S, et al. Curcumin reverses T cell-mediated adaptive Immune Dysfunctions in Tumor-Bearing Hosts. Cell Mol Immunol. 2010;7(4):306–15. https://doi.org/10.1038/cmi.2010.11.CrossRefPubMedPubMedCentral

60.

Fu X, He Y, Li M, Huang Z, Najafi M. Targeting of the tumor microenvironment by curcumin. BioFactors. 2021;47(6):914–32. https://doi.org/10.1002/biof.1776.CrossRefPubMed

61.

Churchill M, Chadburn A, Bilinski RT, Bertagnolli MM. Inhibition of intestinal tumors by curcumin is associated with changes in the intestinalimmune cell profile. J Surg Res. 2000;89:169–75. https://doi.org/10.1006/jsre.2000.5826.CrossRefPubMed

62.

Guo C, Hou X, Liu Y, Zhang Y, Xu H, Zhao F, et al. Novel Chinese angelica polysaccharide biomimetic nanomedicine to curcumin delivery for hepatocellular carcinoma treatment and immunomodulatory effect. Phytomedicine. 2021;80:153356. https://doi.org/10.1016/j.phymed.2020.153356.CrossRefPubMed

63.

Zhao GJ, Lu ZQ, Tang LM, Wu ZS, Wang DW, Zheng JY, et al. Curcumin inhibits suppressive capacity of naturally occurring CD4 + CD25 + regulatory T cells in mice in vitro. Int Immunopharmacol. 2012;14(1):99–106. https://doi.org/10.1016/j.intimp.2012.06.016.CrossRefPubMed

64.

Wang J, Chu Y, Xu M, Zhang X, Zhou Y, Xu M. miR-21 promotes cell migration and invasion of hepatocellular carcinoma by targeting KLF5. Oncol Lett. 2019;17(2):2221–7. https://doi.org/10.3892/ol.2018.9843.CrossRefPubMed

65.

Li ZB, Li ZZ, Li L, Chu HT, Jia M. MiR-21 and miR-183 can simultaneously target SOCS6 and modulate growth and invasion of hepatocellular carcinoma (HCC) cells. Eur Rev Med Pharmacol Sci. 2015;19(17):3208–17.PubMed

66.

Chen S, Yang C, Sun C, Sun Y, Yang Z, Cheng S, et al. Mir-21-5p suppressed the sensitivity of hepatocellular carcinoma cells to cisplatin by targeting FASLG. DNA Cell Biol. 2019;38(8):865–73. https://doi.org/10.1089/dna.2018.4529.CrossRefPubMed

67.

Wang X, Zhang J, Zhou L, Lu P, Zheng ZG, Sun W, et al. Significance of serum microRNA-21 in diagnosis of hepatocellular carcinoma (HCC): clinical analyses of patients and an HCC rat model. Int J Clin Exp Pathol. 2015;8:1466–78.PubMedPubMedCentral

68.

Faloppi L, Scartozzi M, Bianconi M, Svegliati Baroni G, Toniutto P, Giampieri R, et al. The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. BMC Cancer. 2014;14:110. https://doi.org/10.1186/1471-2407-14-110.CrossRefPubMedPubMedCentral

69.

Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol. 2002;64:993–8.CrossRefPubMed

70.

Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol. 2000;88:1474–80.CrossRefPubMed

71.

Dei Cas M, Ghidoni R. Dietary curcumin: correlation between bioavailability and health potential. Nutrients. 2019;11(9):2147. https://doi.org/10.3390/nu11092147.CrossRefPubMedPubMedCentral

72.

Volak LP, Hanley MJ, Masse G, Hazarika S, Harmatz JS, Badmaev V, et al. Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2013;75(2):450–62. https://doi.org/10.1111/j.1365-2125.2012.04364.x.CrossRefPubMed

73.

Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353–6. https://doi.org/10.1055/s-2006-957450.CrossRefPubMed

74.

Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–18. https://doi.org/10.1021/mp700113r.CrossRefPubMed

Title: The potential immuno-stimulating effect of curcumin, piperine, and taurine combination in hepatocellular carcinoma; a pilot study
Authors: Raghda R. kotb
Ahmed M. Afifi
Motawa E. EL-Houseini
Mohamed Ezz-Elarab
Emad B. Basalious
Mervat M. Omran
Mona S. Abdellateif
Publication date: 01-12-2023
Publisher: Springer US
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-023-00785-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Targeting XPO6 inhibits prostate cancer progression and enhances the suppressive efficacy of docetaxel

TRIP13 overexpression in hepatocellular carcinoma: implications for poor prognosis and immune cell infiltration

TOM40 regulates the progression of nasopharyngeal carcinoma through ROS-mediated AKT/mTOR and p53 signaling

Exploring oncogenes for renal clear cell carcinoma based on G protein-coupled receptor-associated genes

Necroptosis-related genes are associated with prognostic features of kidney renal clear cell carcinoma

The interplay between N6-methyladenosine and precancerous liver disease: molecular functions and mechanisms

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials